Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer

References

• Agus DB, Cordon-Cardo C, Fox W, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999 Nov 3;91(21):1869–1876.
   PubMed Web of Science ®Google Scholar
• Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the dunning R-3327-H adenocarcinoma. Cancer Res. 1981 Dec;41(12 Pt 1):5070–5075.
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002 Jul;168(1):9–12.
   PubMed Web of Science ®Google Scholar
• Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 2016 Jan;14(1):19–30.
   PubMed Web of Science ®Google Scholar
• Trachtenberg J, Gittleman M, Steidle C, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 2002 Apr;167(4):1670–1674.
   PubMed Web of Science ®Google Scholar
• Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007 Apr 20;25(12):1596–1605.
   PubMed Web of Science ®Google Scholar
• Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000 Apr 29;355(9214):1491–1498.
   PubMed Web of Science ®Google Scholar
• Laufer M, Denmeade SR, Sinibaldi VJ, et al. Complete androgen blockade for prostate cancer: what went wrong? J Urol. 2000 Jul;164(1):3–9.
   PubMed Web of Science ®Google Scholar
• Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002 Jul 15;95(2):361–376.
   PubMed Web of Science ®Google Scholar
• Belchetz PE, Plant TM, Nakai Y, et al. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science (New York, NY). 1978 Nov 10;202(4368):631–633.
   Google Scholar
• Reiter E, Lefkowitz RJ. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab. 2006 May-Jun;17(4):159–165.
   PubMed Web of Science ®Google Scholar
• Huhtaniemi I, White R, McArdle CA, et al. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab. 2009 Jan;20(1):43–50.
   PubMed Web of Science ®Google Scholar
• Labrie F, Belanger A, Luu-The V, et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev. 2005 May;26(3):361–379.
   PubMed Web of Science ®Google Scholar
• Mahler C. Is disease flare a problem? Cancer. 1993 Dec 15;72(12 Suppl):3799–3802.
   PubMed Web of Science ®Google Scholar
• Klotz L, O’Callaghan C, Ding K, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015 Apr 1;33(10):1151–1156.
   PubMed Web of Science ®Google Scholar
• Schally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971 Apr 16;43(2):393–399.
   PubMed Web of Science ®Google Scholar
• Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA. 1982 Mar;79(5):1658–1662.
   PubMed Web of Science ®Google Scholar
• Rick FG, Block NL, Schally AV. Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert Opin Pharmacother. 2013 Nov;14(16):2237–2247.
   PubMed Web of Science ®Google Scholar
• Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides. 1999;20(10):1247–1262.
   PubMed Web of Science ®Google Scholar
• Limonta P, Montagnani Marelli M, Mai S, et al. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev. 2012 Oct;33(5):784–811.
   PubMed Web of Science ®Google Scholar
• Moreau JP, Delavault P, Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Clin Ther. 2006 Oct;28(10):1485–1508.
   PubMed Web of Science ®Google Scholar
• Heyns CF, Simonin MP, Grosgurin P, et al. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003 Aug;92(3):226–231.
   PubMed Web of Science ®Google Scholar
• Yri OE, Bjoro T, Fossa SD. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol. 2006 Jan;49(1):54–58. discussion 58.
   PubMed Web of Science ®Google Scholar
• Marzouk S, Naglie G, Tomlinson G, et al. Impact of androgen deprivation therapy on self-reported cognitive function in men with prostate cancer. J Urol. 2018 Aug;200(2):327–334.
   PubMed Web of Science ®Google Scholar
• Sun M, Cole AP, Hanna N, et al. Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2018 Jun;199(6):1417–1425.
   PubMed Web of Science ®Google Scholar
• Gunlusoy B, Ceylan Y, Koskderelioglu A, et al. Cognitive effects of androgen deprivation therapy in men with advanced prostate cancer. Urology. 2017;103:167–172.
   PubMed Web of Science ®Google Scholar
• Tae BS, Jeon BJ, Shin SH, et al. Correlation of androgen deprivation therapy with cognitive dysfunction in patients with prostate cancer: a nationwide population-based study using the national health insurance service database. Cancer Res Treat. 2018 Jul 18. doi: 10.4143/crt.2018.119. [Epub ahead of print]. PMID 30025445. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=Correlation+of+androgen+deprivation+therapy+with+cognitive+dysfunction+in+patients+with+prostate+cancer%3A+a+nationwide+populationbased+study+using+the+national+health+insurance+service+database
   Google Scholar
• Cary KC, Singla N, Cowan JE, et al. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE registry. J Urol. 2014 Apr;191(4):964–970.
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011 Dec 7;306(21):2359–2366.
   PubMed Web of Science ®Google Scholar
• Nagy A, Plonowski A, Schally AV. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. Proc Natl Acad Sci USA. 2000 Jan 18;97(2):829–834.
   PubMed Web of Science ®Google Scholar
• Nagy A, Schally AV, Armatis P, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500–1000 times more potent. Proc Natl Acad Sci USA. 1996 Jul 9;93(14):7269–7273.
   PubMed Web of Science ®Google Scholar
• Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab. 2004 Sep;15(7):300–310.
   PubMed Web of Science ®Google Scholar
• Westphalen S, Kotulla G, Kaiser F, et al. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol. 2000 Nov;17(5):1063–1069.
   PubMed Web of Science ®Google Scholar
• Emons G, Gorchev G, Harter P, et al. Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5). Int J Gynecol Cancer. 2014 Feb;24(2):260–265.
   PubMed Web of Science ®Google Scholar
• Emons G, Gorchev G, Sehouli J, et al. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5). Gynecol Oncol. 2014 Jun;133(3):427–432.
   PubMed Web of Science ®Google Scholar
• Yu SS, Athreya K, Liu SV, et al. A phase II trial of AEZS-108 in castration- and taxane-resistant prostate cancer. Clin Genitourin Cancer. 2017 Dec;15(6):742–749.
   PubMed Web of Science ®Google Scholar
• Liu SV, Tsao-Wei DD, Xiong S, et al. Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer. Clin Cancer Res. 2014 Dec 15;20(24):6277–6283.
   PubMed Web of Science ®Google Scholar
• Halmos G, Arencibia JM, Schally AV, et al. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol. 2000 Feb;163(2):623–629.
   PubMed Web of Science ®Google Scholar
• Liu SV, Schally AV, Hawes D, et al. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin Cancer Res. 2010 Sep 15;16(18):4675–4680.
   PubMed Web of Science ®Google Scholar
• Letsch M, Schally AV, Szepeshazi K, et al. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res. 2003 Oct 1;9(12):4505–4513.
   PubMed Web of Science ®Google Scholar
• Popovics P, Schally AV, Szalontay L, et al. Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels. Oncotarget. 2014 Jun 30;5(12):4567–4578.
   PubMedGoogle Scholar
• Fizazi K, Albiges L, Loriot Y, et al. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2015;15(9):1007–1017.
   PubMed Web of Science ®Google Scholar
• Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015 Jul 3;5:12007.
   PubMed Web of Science ®Google Scholar
• Borgmann H, Lallous N, Ozistanbullu D, et al. Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201). Eur Urol. 2018 Jan;73(1):4–8.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Massard C, Bono P, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014 Aug;15(9):975–985.
   PubMed Web of Science ®Google Scholar
• Massard C, Penttinen HM, Vjaters E, et al. Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016 May;69(5):834–840.
   PubMed Web of Science ®Google Scholar
• Cabeza M, Sanchez-Marquez A, Garrido M, et al. Recent advances in drug design and drug discovery for androgen- dependent diseases. Curr Med Chem. 2016;23(8):792–815.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Martel C, Labrie F. Steroid derivatives as pure antagonists of the androgen receptor. J Steroid Biochem Mol Biol. 2012 Oct;132(1–2):93–104.
   PubMed Web of Science ®Google Scholar
• Salvador JA, Carvalho JF, Neves MA, et al. Anticancer steroids: linking natural and semi-synthetic compounds. Nat Prod Rep. 2013 Feb;30(2):324–374.
   PubMed Web of Science ®Google Scholar
• Tong Y, Chen C, Wu J, et al. Abstract 614: proxalutamide (GT0918), a potent androgen receptor pathway inhibitor. Cancer Res. 2014;74(19 Suppl):614.
   Web of Science ®Google Scholar
• Tong Y, Chen C, Wu J, et al. Abstract 2460: discovery of potent androgen receptor antagonists for treating CRPC and AR+ breast cancer. Cancer Res. 2014;73(8 Suppl):2460.
   Google Scholar
• Zhou T, Xu W, Xu C, et al. A first-in-human phase 1 study of proxalutamide (GT0918), a dual MOA androgen receptor blocker in patients with advanced CRPC. J Clin Oncol. 2017;35(suppl): abstre16511.
   Google Scholar
• Rafferty SW, Eisner JR, Moore WR, et al. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors. Bioorg Med Chem Lett. 2014 Jun 1;24(11):2444–2447.
   PubMed Web of Science ®Google Scholar
• Stein MN, Patel N, Bershadskiy A, et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl. 2014 May-Jun;16(3):387–400.
   PubMed Web of Science ®Google Scholar
• Toren PJ, Kim S, Pham S, et al. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol Cancer Ther. 2015 Jan;14(1):59–69.
   PubMed Web of Science ®Google Scholar
• Miwa K, Hitaka T, Imada T, et al. Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2011 Jul 28;54(14):4998–5012.
   PubMed Web of Science ®Google Scholar
• Nakata D, Masaki T, Tanaka A, et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014 Jan 15;723:167–174.
   PubMed Web of Science ®Google Scholar
• Streuli I, de Ziegler D, Borghese B, et al. New treatment strategies and emerging drugs in endometriosis. Expert Opin Emerg Drugs. 2012 Mar 23.. [Epub ahead of print]. PMID 22439891. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=New+treatment+strategies+and+emerging+drugs+in+endometriosis
   PubMed Web of Science ®Google Scholar
• MacLean DB, Shi H, Faessel HM, et al. Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): phase 1 study in healthy males. J Clin Endocrinol Metab. 2015 Dec;100(12):4579–4587.
   PubMed Web of Science ®Google Scholar
• Saad F, Bailen JL, Pieczonka CM, et al. Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts). J Clin Oncol. 2016;34(2 Suppl):200.
   Google Scholar
• Shore ND, Bailen JL, Pieczonka C, et al. PD28-01 Testosterone lowering, PSA response and quality of life in patients with advanced hormone sensitive prostate cancer receiving TAK-385, an oral GnRH antagonist: phase 2 interim analysis. J Urol. 2016;195(4 Suppl):e654.
   Web of Science ®Google Scholar
• Dearnaley D, Saltzstein DR, Sylvester JE, et al. Phase 2 study of investigational oral GnRH antagonist TAK385 (relugolix) in patients with intermediate risk localized prostate cancer requiring neoadjuvant and adjuvant androgen deprivation therapy (ADT) with external beam radiation therapy (EBRT): results from the 12-week interim analysis. Eur Urol Suppl. 2015;14:145–146.
   Google Scholar
• Dearnaley D, Saltzstein DR, Sylvester JE, et al. Neo/adjuvant ADT to EBRT: randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC). Ann Oncol. 2016;27(6 Suppl):734P.
   Google Scholar
• Coss CC, Jones A, Parke DN, et al. Preclinical characterization of a novel diphenyl benzamide selective ERalpha agonist for hormone therapy in prostate cancer. Endocrinology. 2012 Mar;153(3):1070–1081.
   PubMed Web of Science ®Google Scholar
• Yu EY, Getzenberg RH, Coss CC, et al. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb;67(2):334–341.
   PubMed Web of Science ®Google Scholar
• Jones A, Getzenberg RH, Dalton JT, et al. 1448 oral administration of GTx-758, a selective ERa agonist, induces chemical castration but not gynecomastia in male monkeys. J Urol. 2011;185(4 Suppl):e581.
   Web of Science ®Google Scholar
• Yu EY, Hancock ML, Babicz T, et al. Effect of the ERα agonist, GTx-758 (250 mg daily), on total and free testosterone, and PSA, in men with castration resistant prostate cancer (CRPC) maintained on LHRH therapy. J Clin Oncol. 2015;33(Suppl):e16020.
   Google Scholar
• Katkam RR, Gopalkrishnan K, Chwalisz K, et al. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception. Am J Obstet Gynecol. 1995 Sep;173(3 Pt 1):779–787.
   PubMed Web of Science ®Google Scholar
• Robertson JF, Willsher PC, Winterbottom L, et al. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999 Feb;35(2):214–218.
   PubMed Web of Science ®Google Scholar
• Jayaram A, Nowakowska K, Mateo J, et al. Phase 1–2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status. Ann Oncol. 2017;28(Suppl 7): abstract72:vii30.
   PubMedGoogle Scholar
• Langley RE, Godsland IF, Kynaston H, et al. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int. 2008 Aug;102(4):442–445.
   PubMed Web of Science ®Google Scholar
• Langley RE, Cafferty FH, Alhasso AA, et al. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol. 2013 Apr;14(4):306–316.
   PubMed Web of Science ®Google Scholar
• Gilbert DC, Duong T, Kynaston HG, et al. Quality-of-life outcomes from the prostate adenocarcinoma: transcutaneous hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer. BJU Int. 2017 May;119(5):667–675.
   PubMed Web of Science ®Google Scholar
• Langley RE, Kynaston HG, Alhasso AA, et al. A randomised comparison evaluating changes in bone mineral density in advanced prostate cancer: luteinising hormone-releasing hormone agonists versus transdermal oestradiol. Eur Urol. 2016 Jun;69(6):1016–1025.
   PubMed Web of Science ®Google Scholar
• Gilbert DC, Duong T, Sydes M, et al. Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. BJU Int. 2018 May;121(5):680–683.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Zahurak M, Schaeffer EM, et al. Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). J Clin Oncol. 2017;35(15 Suppl):5077.
   Google Scholar
• Rl B, Aj A. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013 Jun;20(3):R83–99.
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010 Jul 13;18(1):11–22.
   PubMed Web of Science ®Google Scholar
• Mulholland DJ, Tran LM, Li Y, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011 Jun 14;19(6):792–804.
   PubMed Web of Science ®Google Scholar
• Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011 May 17;19(5):575–586.
   PubMed Web of Science ®Google Scholar
• Liu L, Dong X. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells. PloS one. 2014;9(10):e108780.
   PubMed Web of Science ®Google Scholar
• Hsieh AC, Nguyen HG, Wen L, et al. Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors. Sci Signal. 2015 Nov 17;8(403):ra116.
   PubMed Web of Science ®Google Scholar
• Yan G, Ru Y, Wu K, et al. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling. Prostate. 2018 Feb;78(3):166–177.
   PubMed Web of Science ®Google Scholar
• Yadav SS, Li J, Stockert JA, et al. Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer. Oncotarget. 2016 Nov 15;7(46):76181–76196.
   PubMedGoogle Scholar
• Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012 Jan 20;30(3):282–290.
   PubMed Web of Science ®Google Scholar
• Burris H, Rodon J, Sharma S, et al. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J clin oncol. 2010;28(15_suppl):3005.
   Google Scholar
• Massard C, Chi KN, Castellano D, et al. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. Eur J Cancer. 2017;76:36–44.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Halabi S, Healy P, et al. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer. Eur J Cancer. 2017;81:228–236.
   PubMed Web of Science ®Google Scholar
• Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008 May 1;68(9):3323–3333.
   PubMed Web of Science ®Google Scholar
• Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005 Oct 15;65(20):9185–9189.
   PubMed Web of Science ®Google Scholar
• Araujo JC, Mathew P, Armstrong AJ, et al. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1–2 study. Cancer. 2012 Jan 1;118(1):63–71.
   PubMed Web of Science ®Google Scholar
• Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013 Dec;14(13):1307–1316.
   PubMed Web of Science ®Google Scholar
• Kato S, Jardim DL, Johnson FM, et al. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 Jun;36(3):416–423.
   PubMed Web of Science ®Google Scholar
• Spreafico A, Chi KN, Sridhar SS, et al. A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs. 2014 Oct;32(5):1005–1016.
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615–2622.
   PubMed Web of Science ®Google Scholar
• Aras B, Yerlikaya A. Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3. Oncol Lett. 2016 May;11(5):3179–3184.
   PubMed Web of Science ®Google Scholar
• Canfield SE, Zhu K, Williams SA, et al. Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol Cancer Ther. 2006 Aug;5(8):2043–2050.
   PubMed Web of Science ®Google Scholar
• Cao W, Shiverick KT, Namiki K, et al. Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol. 2008 Oct;26(5):509–516.
   PubMed Web of Science ®Google Scholar
• An J, Sun YP, Adams J, et al. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2003 Oct 1;9(12):4537–4545.
   PubMed Web of Science ®Google Scholar
• LoConte NK, Thomas JP, Alberti D, et al. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemother Pharmacol. 2008 Dec;63(1):109–115.
   PubMed Web of Science ®Google Scholar
• Cresta S, Sessa C, Catapano CV, et al. Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer. 2008 Sep;44(13):1829–1834.
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Meluch AA, Spigel DR, et al. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a minnie pearl cancer research network phase II trial. Clin Genitourin Cancer. 2007 Mar;5(4):278–283.
   PubMed Web of Science ®Google Scholar
• Kraft AS, Garrett-Mayer E, Wahlquist AE, et al. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15;12(2):119–124.
   PubMed Web of Science ®Google Scholar
• Meng Y, Tang W, Dai Y, et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther. 2008 7;Jul(7):2192–2202.
   Google Scholar
• McGregor N, Patel L, Craig M, et al. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. J Cell Biochem. 2010 Aug 1;110(5):1187–1194.
   PubMed Web of Science ®Google Scholar
• Jiang J, Slivova V, Jedinak A, et al. Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-kappaB/AP-1 dependent- and independent-signaling. Clin Exp Metastasis. 2012 Feb;29(2):165–178.
   PubMed Web of Science ®Google Scholar
• Huang YW, Wang LS, Dowd MK, et al. (-)-Gossypol reduces invasiveness in metastatic prostate cancer cells. Anticancer Res. 2009 Jun;29(6):2179–2188.
   PubMed Web of Science ®Google Scholar
• Jin CL, Chen ML, Wang Y, et al. Preparation of novel (-)-gossypol nanoparticles and the effect on growth inhibition in human prostate cancer PC-3 cells in vitro. Exp Ther Med. 2015 Mar;9(3):675–678.
   PubMed Web of Science ®Google Scholar
• Liu G, Wk K, Wilding G, et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2009 May 1;15(9):3172–3176.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Matveev V, Burke JM, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012 Jul;23(7):1803–1808.
   PubMed Web of Science ®Google Scholar
• Stein MN, Hussain M, Stadler WM, et al. A phase II study of AT-101 to overcome Bcl-2–mediated resistance to androgen deprivation therapy in patients with newly diagnosed castration-sensitive metastatic prostate cancer. Clin Genitourin Cancer. 2016 Feb;14(1):22–27.
   PubMed Web of Science ®Google Scholar
• Lin J, Patel SA, Sama AR, et al. A phase I/II study of the Investigational drug alisertib in combination with abiraterone and prednisone for patients with metastatic castration-resistant prostate cancer progressing on abiraterone. Oncologist. 2016 Nov;21(11):1296e–1297e.
   PubMed Web of Science ®Google Scholar
• Goldman J, Eckhardt SG, Borad MJ, et al. Phase I dose-escalation trial of the oral investigational hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 1;21(5):1002–1009.
   PubMed Web of Science ®Google Scholar
• Ibuki N, Ghaffari M, Pandey M, et al. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer. 2013 Oct 15;133(8):1955–1966.
   PubMed Web of Science ®Google Scholar
• Lowrance WT, Murad MH, Oh WK, et al. castration-resistant prostate cancer: AUA guideline amendment 2018. J Urol. 2018 Dec;200(6):1264–1272.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017 Jul 27;377(4):352–360.
   PubMed Web of Science ®Google Scholar
• Wedge DC, Gundem G, Mitchell T, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. 2018 May;50(5):682–692.
   PubMed Web of Science ®Google Scholar
• Armenia J, Sam W, Liu D, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 May;50(5):645–651.
   PubMed Web of Science ®Google Scholar
• Yin Y, Li R, Xu K, et al. Androgen receptor variants mediate DNA repair after prostate cancer irradiation. Cancer Res. 2017 Sep 15;77(18):4745–4754.
   PubMed Web of Science ®Google Scholar
• Kelsey R. Prostate cancer: genomic drivers of resistance to AR therapies. Nat Rev Urol. 2018 Apr;15(4):202.
   Google Scholar